MicroRNA 373 mimic - IPS HEART
Alternative Names: Micro-RNA 373 mimic; MIR-373Latest Information Update: 15 Jan 2024
At a glance
- Originator IPS HEART
- Class Antifibrotics; Exosome therapies; Heart failure therapies; MicroRNAs
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis; Heart failure
Most Recent Events
- 28 Nov 2023 Preclinical trials in Fibrosis in USA (Parenteral) before November 2023 (IPS Heart pipeline, November 2023)
- 28 Nov 2023 Preclinical trials in Heart failure in USA (Parenteral) before November 2023 (IPS Heart pipeline, November 2023)
- 19 Feb 2020 IPS HEART has a patent pending for microRNA 373 mimic in USA